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In this issue of Cancer Cell, Xiao et al. report that PLC-b3 mutant mice develop myeloprolfierative neoplasms
and show that tumor suppressor activity does not require PLC-b3 catalytic activity. Instead, PLC-b3 forms
a complex with SHP-1 and Stat5 that facilitates Stat5 dephosphorylation. A similar mechanism may be oper-
ative in some human leukemias.Subversion of growth factor signaling is a
hallmark of oncogenesis. This has imme-
diate therapeutic implications because
specific classes of signal transduction
molecules, such as tyrosine kinases, have
proven amenable to inhibition by small
molecules. Whereas studies in which on-
coproteins were overexpressed in immor-
talized cell lines and heterologous tissues
defined the basic architecture of canonical
cancer signaling pathways, it has become
increasingly clear that the biochemical
wiring of primary neoplastic cells is more
nuanced and complicated. This is due to
both the inherent ability of cells to remodel
signaling networks in response to stress
and to the profound complexity of sig-
naling networks. One factor underlying
this complexity is the sheer number of
molecules involved in the response to
many stimuli. This is exacerbated by the
coexpression of structurally distinct iso-
forms of many enzymes, generated from
related genes or through alternative
splicing of a single gene. Furthermore, in-
terlocking feedback loops create highly
dynamic and nonlinear response charac-
teristics in networks. Finally, the repertoire
of growth factor receptors, adaptors, and
downstream network components varies
widely among distinct cell types.
In this issue, Xiao et al. use mouse
genetics as a starting point for investi-
gating the consequences of disrupting the
b3 isozyme of phospholipase C (PLC-b3)
(Xiao et al., 2009). They unexpectedly
found that PLC-b3 functions as a tumor
suppressor in hematopoietic cells, per-
formed incisive biochemical studies that
implicate PLC-b3 as a negative regulator
of Stat5 signaling, and reported intriguing
preliminary observations in human cells.Like the other 12 members of the phos-
pholipase C family, PLC-b3 catalyzes the
conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol-1,4,5-tri-
sphosphate (IP3) and diacylglycerol (DAG)
(Figure 1A) (Suh et al., 2008). These
second messengers are positive regula-
tors of mitogenic signaling—IP3 induces
calcium release from intracellular stores
and DAG can initiate activation of Ras
proteins via the RasGRP family of guanine
nucleotide exchange factors. Calciumand
DAG also activate protein kinase C,
among other targets. The four members
of the PLCb subfamily are implicated as
promotingcell growthdownstreamof acti-
vated G protein coupled receptors. Given
this conventional view of PLC function, it
is surprising that Xiao et al. found that
mice deficient for PLC-b3 developed a
neoplastic disease. Specifically, older
mice frequently developed a myeloprolif-
erative neoplasm (MPN), a differentiated
hematopoietic malignancy that is fre-
quently caused by mutations that activate
signaling molecules such as BCR-ABL,
N-Ras, SHP-2, and JAK-2 (Van Etten and
Shannon, 2004). The authors pursued
this initial observation in three ways.
First, theyusedstate-of-the-artmethods
to evaluate the hematopoietic compart-
ment in PLC-b3/ mice. Stem and pro-
genitor populations were expanded in the
absence of PLC-b3 and demonstrated
excessive proliferation in vivo and in vitro.
Importantly, myeloid hyperplasia devel-
oped in naive recipients that were trans-
planted with PLC-b3/ bone marrow
cells, which demonstrates that the ab-
normal accumulation and infiltration of
myeloid lineage cells is intrinsic to the
hematopoietic system. The observationCancer Cethat the leukemia initiating population is
restricted to the c-kit+ lineage- Sca1+
(KLS) CD34 fraction is consistent with
other murine models of MPN in which
hematopoietic stem cells (HSCs), but not
their more differentiated progeny, can
transfer disease in vivo (Sabnis et al.,
2009; Santaguida et al., 2009). Adoptive
transfer and competitive reconstitution
experiments using cells sorted based on
expression of more selective stem cell
markers, such as those in the signaling
lymphocytic activation molecule (SLAM)
family, will provide more precise informa-
tion on the phenotypic and biologic char-
acteristics of the leukemia-initiating popu-
lation in this model (Kiel et al., 2005).
The authors next sought a biochemical
mechanism to explain the tumor sup-
pressor activity of PLC-b3. A key observa-
tion was hyperphosphorylation of Stat5
in multipotent progenitor cells. Stat5 is a
key regulator of proliferation and survival
downstream of activated cytokine recep-
tors that are aberrantly activated in many
myeloid malignancies (Murray, 2007). To
assess the functional relevance of Stat5
to myeloproliferation, the authors infected
PLC-b3/ bonemarrowcellswith a domi-
nant-negative Stat5 construct and found
that this attenuated the ability of thesecells
to cause MPN in vivo. Importantly, ex-
pressing not only wild-type PLC-b3, but
also a PLC-b3 protein lacking catalytic
activity reduced proliferation and Stat5
phosphorylation. The authors went on to
identify a carboxyl-terminal fragment of
PLC-b3 as essential for biologic functions.
How then, does loss of this PLC-b3
adaptor activity deregulate Stat5 sig-
naling? Xiao and colleagues performed
a comprehensive biochemical analysis inll 16, August 4, 2009 ª2009 Elsevier Inc. 87
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Previewsthe Ba/F3 lymphoid cell line to elucidate
the underlying mechanism. These cells
are an ideal choice, as they depend upon
interleukin 3, a cytokine that activates
Stat5, for growth and survival. The authors
demonstrate a tripartite ‘‘SPS’’ complex
that includes PLC-b3, Stat5, and the
protein tyrosine phosphatase SHP-1 and
implicated phosphorylated Stat5 as a
Figure 1. Distinct Roles of PLC-b3 inGrowth
Regulation
(A) PLC-b3 is a positive effector of mitogenic
signals downstream of G-protein-coupled recep-
tors. When a growth factor (GF) binds to its
receptor, the associated Ga subunit becomes
GTP-bound. This recruits PLC-b3, which cleaves
PIP2 into IP3 and DAG. IP3 induces calcium release
from intracellular stores. These second messen-
gers coordinately activate multiple signal trans-
duction proteins, most notably protein kinase C
(PKC) and RasGRP. These, in turn, initiate mito-
genic signaling through Ras and the mitogen-acti-
vated protein kinase pathway.
(B) PLC-b3 attenuates JAK/Stat signaling. Recep-
tors for cytokines and related ligands lack intrinsic
kinase activity and instead initiate signaling by acti-
vating the protein tyrosine kinase JAK2. This
results in phosphorylation of the receptor and other
JAK2 substrates, such as Stat5. Phosphorylated
Stat5 translocates to the nucleus and acts as
a transcription factor. In this issue of Cancer Cell,
Xiao et al. demonstrate that a carboxyl terminal
domain of PLC-b3 can recruit the protein tyrosine
phosphatase SHP-1 to Stat5, resulting in its
dephosphorylation. This novel, growth inhibitory
activity of PLC-b3 is required to prevent neoplasia
in the hematopoietic system.88 Cancer Cell 16, August 4, 2009 ª2009 ElsSHP-1 substrate. Genetic and functional
analysis of motheaten viable (Mev/Mev)
mice, which have a hypomorphic allele of
the gene encoding SHP-1, affirmed the
functional importance of SHP-1 phospha-
tase activity in theSPScomplex. Together,
thesestudies stronglysupport the idea that
the carboxyl terminus of PLC-b3 restrains
hematopoietic growth by colocalizing acti-
vatedStat5 andSHP-1, therebypromoting
Stat5dephosphorylation (Figure1B).While
the current studies do not directly address
if specific cytokines are essential cocon-
spirators in thedevelopment ofMPN, there
are intriguing candidates. The thrombo-
poietin receptor is expressed on HSC and
signals, in part, through Stat5. PLC-b3
mutant myeloid progenitors are also
hypersensitive to both IL-3 and granulo-
cyte-macrophage colony stimulating
factor (GM-CSF). Interestingly, aberrant
Stat5activation in response to lowconcen-
trations of GM-CSF is a biochemical
feature of the juvenile myelomonocytic
leukemia and chronic myelomonocytic
leukemia subtypes of human MPN (Kote-
cha et al., 2008).
A final aspect of this ambitious and far-
ranging paper is studies addressing the
role of PLC-b3 in lymphoma and lymphoid
leukemia. The authors find that loss of
PLC-b3 cooperates with deregulated
Myc expression in a classic model of B
lineage leukemia. In this system, mice
that are heterozygous for themutant allele
show markedly reduced PLC-b3 protein
expression in the absence of ‘‘second
hit’’ mutations. Consistent with this, two
of six human Burkitt’s lymphoma cell lines
showed low levels of PLC-b3 and elevated
Stat5 phosphorylation. Overexpressing
PLC-b3 inhibited the growth of these cells,
but not of a line that showed high endoge-
nous levels of theprotein. The authors also
identified a subset of human chronic lym-
phocytic leukemia samples that showed
concomitant elevated levels of phosphor-
ylated Stat5 and low PLC-b3 expression.
These intriguing correlative data set the
stage for future experiments to under-
stand the mechanisms underlying re-
duced PLC-b3 expression in some human
cancers, to determine if there is a cause-
and-effect relationship with deregulated
Stat5 signaling, and to investigate if
a hematopoietic malignancies with this
biochemical profile are uniquely sensitiveevier Inc.to small molecule inhibitors that interfere
with Stat5 activation or output.
A provocative aspect of this work is that
an important physiologic role of PLC-b3
is encoded in a noncatalytic domain.
Furthermore, this unexpected new tumor
suppressoractivityofPLC-b3mayoppose
(or at least counterbalance) other growth-
promoting properties of the protein that
are mediated by the production of IP3
and DAG. Taken together, the results of
Xiao and colleagues demonstrate that it
may be impossible to functionally catego-
rize signal transduction proteins using
simple binary concepts. Indeed, in cellular
contexts where Stat5 is not expressed,
PLC-b3 may have predominately pro-
growth properties. Alternatively, the
absence of PLC-b3 mutations in human
cancers may reflect the fact that complete
loss of protein function may negatively
impact cell fitness. New analytical tools
may be required to represent the compli-
cated interactions of multidomain sig-
naling proteins. In the meantime, the
rigorous studies of Xiao et al. provide an
excellent example of how interrogating
primary cells with a defined genetic alter-
ation can uncover novel and unanticipated
biochemical interactions that are physio-
logically important in growth regulation
and oncogenesis.
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